Skip to main content
TipRanks
Go Ultimate75% OFF

Opus Genetics (IRD) Stock Price & Analysis

1,367 Followers

IRD Stock Chart & Stats

$3.98-$0.08(-1.97%)
At close: 4:00 PM EST
$4$5$6Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$3.80 - $4.17
52-Week Range
$1.70 - $7.07
Previous Close
$4.06
Volume
N/A
Average Volume (3M)
1.40M
Market Cap
$384.68M
Enterprise Value
$439.82M
Total Cash (Recent Filing)
$88.97M
Total Debt (Recent Filing)
$34.53M
Price to Earnings (P/E)
―
Beta
0.60
Next Earnings
Mar 11, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical And Regulatory Progress

Positive clinical findings combined with FDA alignment reduce development uncertainty for OPGx-BEST1. If follow-up data remain supportive, the clearer endpoint and planned pivotal path could improve the program’s probability of advancing toward commercialization.

OPGx-LCA5 Phase 3 Advancement

A fully enrolled registrational trial represents meaningful execution progress and moves OPGx-LCA5 closer to a potential regulatory decision. This creates a nearer-term development milestone and diversifies the company’s clinical pipeline beyond earlier-stage programs.

Expanding Gene Therapy Pipeline

IND clearance for a third gene therapy program broadens Opus Genetics’ pipeline and supports a multi-asset development strategy. Additional programs can create more opportunities for clinical success and reduce reliance on any single inherited retinal disease candidate.

Bears Say

Contracting Revenue

Declining revenue indicates that the company’s current commercial or partnered revenue base is not yet providing dependable growth. A smaller revenue foundation limits internal funding capacity and leaves future financial performance highly dependent on clinical and regulatory milestones.

Severe Operating Losses

Losses are extremely large relative to the revenue base, showing that operating costs currently overwhelm incoming revenue. Persistent negative profitability can increase dependence on external financing and makes the business more vulnerable if development timelines extend or programs underperform.

Heavy Cash Burn

Sustained negative operating and free cash flow means the company is consuming cash rather than funding development internally. Continued burn implies ongoing financing needs, which may constrain strategic flexibility and could increase dilution or funding pressure while losses persist.

Opus Genetics News

IRD FAQ

What was Opus Genetics’s price range in the past 12 months?
Opus Genetics lowest stock price was $1.70 and its highest was $7.07 in the past 12 months.
What is Opus Genetics’s market cap?
Opus Genetics’s market cap is $384.68M.
When is Opus Genetics’s upcoming earnings report date?
Opus Genetics’s next earnings report is estimated for Mar 11, 2027 (not yet confirmed), which is in 115 days.
How were Opus Genetics’s earnings last quarter?
Opus Genetics released its earnings results on Nov 10, 2026. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.146 by -$0.314.
Is Opus Genetics overvalued?
According to Wall Street analysts Opus Genetics’s price is currently Undervalued.
Does Opus Genetics pay dividends?
Opus Genetics does not currently pay dividends.
What is Opus Genetics’s EPS estimate?
Opus Genetics’s EPS estimate is -0.11.
How many shares outstanding does Opus Genetics have?
Opus Genetics has 96,654,335 shares outstanding.
What happened to Opus Genetics’s price movement after its last earnings report?
Opus Genetics reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.146. Following the earnings report the stock price went up 0.714%.
Which hedge fund is a major shareholder of Opus Genetics?
Hedge funds hold Opus Genetics shares: the largest hedge-fund position in Opus Genetics is 72,325,981 shares, and hedge funds increased their holdings by 264.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology